A Novel Protocol for Directed Differentiation of C9orf72-Associated Human Induced Pluripotent Stem Cells Into Contractile Skeletal Myotubes by Swartz, Elliot W. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2016-11-01 
A Novel Protocol for Directed Differentiation of 
C9orf72-Associated Human Induced Pluripotent Stem Cells Into 
Contractile Skeletal Myotubes 
Elliot W. Swartz 
University of California, Los Angeles 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cell Biology Commons, Developmental Biology Commons, and the Translational Medical 
Research Commons 
Repository Citation 
Swartz EW, Baek J, Pribadi M, Wojta KJ, Almeida S, Karydas AM, Gao F, Miller BL, Coppola G. (2016). A 
Novel Protocol for Directed Differentiation of C9orf72-Associated Human Induced Pluripotent Stem Cells 
Into Contractile Skeletal Myotubes. Open Access Articles. https://doi.org/10.5966/sctm.2015-0340. 
Retrieved from https://escholarship.umassmed.edu/oapubs/3004 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Pluripotent Stem Cells
A Novel Protocol for Directed Differentiation of
C9orf72-AssociatedHuman InducedPluripotent Stem
Cells Into Contractile Skeletal Myotubes
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ABSTRACT
Induced pluripotent stem cells (iPSCs) offer an unlimited resource of cells to be used for the study of
underlying molecular biology of disease, therapeutic drug screening, and transplant-based regener-
ative medicine. However, methods for the directed differentiation of skeletal muscle for these pur-
poses remain scarce and incomplete. Here,we present a novel, smallmolecule-basedprotocol for the
generation of multinucleated skeletal myotubes using eight independent iPSC lines. Through combi-
natorial inhibition of phosphoinositide 3-kinase (PI3K) and glycogen synthase kinase 3b (GSK3b) with
additionof bonemorphogenic protein 4 (BMP4) and fibroblast growth factor 2 (FGF2),we report up to64%
conversionof iPSCs intothemyogenicprogrambyday36as indicatedbyMYOG+cellpopulations.Thesecells
began to exhibit spontaneous contractions as early as 34 days in vitro in the presence of a serum-freeme-
diumformulation.Weusedthisprotocol toobtain iPSC-derivedmusclecells fromfrontotemporaldementia
(FTD) patients harboring C9orf72 hexanucleotide repeat expansions (rGGGGCC), sporadic FTD, and unaf-
fected controls. iPSCs derived from rGGGGCC carriers containedRNA foci but did not vary in differentiation
efficiencywhencompared tounaffectedcontrols nordisplaymislocalizedTDP-43after asmanyas120days
in vitro. This study presents a rapid, efficient, and transgene-freemethod for generatingmultinucleated skel-
etalmyotubesfromiPSCsandaresourceforfurthermodelingtheroleofskeletalmuscleinamyotrophic lateral
sclerosis and other motor neuron diseases. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1461–1472
SIGNIFICANCE
Protocols to produce skeletal myotubes for disease modeling or therapy are scarce and incomplete.
The present study efficiently generates functional skeletal myotubes from human induced pluripo-
tent stem cells using a small molecule-based approach. Using this strategy, terminalmyogenic induc-
tion of up to 64% in 36 days and spontaneously contractile myotubes within 34 days were achieved.
Myotubes derived from patients carrying the C9orf72 repeat expansion show no change in differen-
tiation efficiency and normal TDP-43 localization after asmany as 120 days in vitrowhen compared to
unaffected controls. This study provides an efficient, novel protocol for the generation of skeletal
myotubes from human induced pluripotent stem cells that may serve as a valuable tool in drug dis-
covery and modeling of musculoskeletal and neuromuscular diseases.
INTRODUCTION
Human embryonic stem cells and, more recently,
induced pluripotent stem cells (iPSCs) have been
heralded for their potential to generate all cell
types of any germ layer, providing avenues for dis-
ease research, drug discovery, and transplantation
[1, 2]. A variety of successful protocols for directed
differentiation of iPSCs into different cell types
haveemerged in recentyears; however, thegener-
ation of skeletal myotubes has proven to be more
challenging. The generation of PAX3+ and PAX7+
paraxial mesoderm progenitors from iPSCs would
serve as a valuable tool for repopulating the satel-
lite cell niche in patients with degenerative disor-
ders such as Duchenne muscular dystrophy, and
the generation of skeletalmyotubes offers options
for drug screening and disease modeling in disor-
ders such as amyotrophic lateral sclerosis (ALS), in-
clusion body myopathy with Paget’s disease and
early-onset frontotemporal dementia (IBMPFD),
and spinal muscular atrophy (SMA).
Initial studies in human and mouse showed
that directed differentiation followed by isolation
of paraxial mesoderm progenitors by flow cytom-
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PLURIPOTENT STEM CELLS
Differentiation efficiencies were later improved by transient ex-
pression of myogenic genes such as PAX3, PAX7, or MYOD1
[6–12]. In regenerative medicine, however, it is desirable to pro-
duce cells absent of genetic modification, which more accurately
replicate development and can be suitable for future clinical appli-
cations [13]. As such, recent protocols have focusedon recapitulat-
ing development via chemically defined, small molecule-based
methods for the generation of paraxial mesoderm progenitors
and mature skeletal myotubes [14–18].
Here we build on previous studies to report an efficient pro-
tocol for thederivationof skeletalmyotubes frompatient-derived
iPSCs. This protocol uses dimethylsulfoxide (DMSO) and phos-
phoinositide 3-kinase (PI3K) inhibition to enhance differentiation
efficiency toward the mesodermal lineage in the presence of
bonemorphogenetic protein 4 (BMP4) and fibroblast growth fac-
tor 2 (FGF2) and promotion of Wnt signaling via glycogen syn-
thase kinase 3b (GSK3b) inhibition, yielding up to 90% of
myogenic cells by exclusive PAX7+/MYOG+ populations after 36
days in vitro. These cells fuse to form spontaneously contractile,
multinucleated myotubes in the presence of serum-free medium
as early as 34 days in vitro, thus providing a viable tool for mod-
eling skeletal muscle diseases.
Given that the contribution of skeletal muscle and the neuro-
muscular junction inmotor neuron diseases such as ALS and SMA
remains largely unexplored, we aimed to study whether patho-
logic phenotypes described in neurons derived from individuals
carrying a pathogenic expansion in C9orf72, the most common
genetic mutation in ALS and frontotemporal dementia (FTD)
[19], could be present in skeletal muscle. Mutations seen in
IBMPFD patients such as VCP and hnRNPA1 overlap with muta-
tions seen in ALS patients, suggesting shared affected pathways
[20]. Interestingly, TDP-43 and ubiquitin pathology observed in
thebrains of repeat expansion carriers is alsopresent in thebrains
and skeletal muscle of IBMPFD patients [21]. We report that
C9orf72 is expressed in iPSC-derived skeletal muscle, which also
contains nuclear RNA foci, one of the hallmarks of pathology in
the brain [19].We also explored potential skeletal muscle pathol-
ogy in iPSCs derived from GGGGCC expansion carriers and con-
trols but observed no aberrant changes in differentiation
efficiencies, TDP-43 localization, nuclear envelope breakdown
via RanGAP1 and lamin A/C (LMNA) immunocytochemistry, and
ubiquitin or p62 pathology.
MATERIALS AND METHODS
Human iPSCs
Fibroblasts were obtained with patient consent and institutional
review board approval (#10-000574) from skin biopsies of pa-
tients diagnosed with C9orf72-related FTD or sporadic FTD and
healthy controls from the University of California, San Francisco,
Memory and Aging Center. Fibroblastswere cultured in Dulbecco’s
modified Eagle’s medium (DMEM) and 10% fetal bovine se-
rum (FBS). Reprogramming was performedwith the STEMCCA
lentiviral vector containing OCT4, c-MYC, SOX2, and KLF4 (EMD
Millipore, Billerica, MA, http://www.emdmillipore.com). Pluri-
potency was assessed via Pluritest [22] and immunocytochem-
ical staining of NANOG, OCT4, SSEA4, and TRA-181. Karyotyping
was performed by Cell Line Genetics in passages 5–25 after
reprogramming. iPSCs were cultured at 37°C and 5% CO2 on
plates coated with vitronectin (Stem Cell Technologies,
Vancouver, BC, Canada, http://www.stemcell.com) in TeSR-E8
medium (Stem Cell Technologies) and passaged every 4–6 days
using ReLeSR reagent (Stem Cell Technologies) according to the
manufacturer’s instructions. Supplemental online Table 1 lists
the iPSC lines used and relevant patient information.
Skeletal Muscle Differentiation
When iPSC colonies were ∼250–400 mm in diameter, 1.5% DMSO
(Sigma-Aldrich, St. Louis, MO, http://www.sigamaaldrich.com) in
TeSR-E8 medium was added. On day 0, cells were cultured in
CDM FLyBC for 36 hours. Chemically defined medium (CDM) con-
sists of a 1:1 mixture of Iscove’s modified Dulbecco’s medium and
Ham’s F12 medium (Thermo Fisher Scientific Life Sciences, Wal-
tham,MA,http://www.thermofisher.com)with theadditionofbo-
vine serum albumin (5 mg/ml; Thermo Fisher Scientific Life
Sciences), 1003 lipids (13; Thermo Fisher Scientific Life Sciences),
transferrin (15 mg/ml; Sigma-Aldrich), 1-thioglycerol (450 mM;
Sigma-Aldrich), and insulin (7 mg/ml; Thermo Fisher Scientific Life
Sciences). FLyBC consists of FGF2 (20 ng/ml; Stem Cell Technolo-
gies), LY294002 (10 mM; Stem Cell Technologies), BMP4 (10 ng/
ml; Stem Cell Technologies), and CHIR99021 (10 mM; Sigma-
Aldrich). After 36 hours, cells were cultured in CDM FLy for an ad-
ditional 5.5days.Onday7, cellswerecultured inMB-1and15%FBS
(three-quarters dailymedium change) donated from the labora-
tory of Dr. Jacques Tremblay (Universite´ Laval, Ville de Que´bec,
QC, Canada) and prepared per that laboratory’s instructions. On
day 12, cellswere cultured in fusionmedium (replaced on alternat-
ing days) consisting of 2% horse serum (Sigma-Aldrich) in DMEM
(Thermo Fisher Scientific Life Sciences). For terminal differentia-
tion, cells were changed to N-2 medium (replaced on alternating
days) consisting of DMEM F12 (Thermo Fisher Scientific Life Sci-
ences) supplementedwith 1%N-2 supplement (Thermo Fisher Sci-
entific Life Sciences) and 1% insulin-transferrin-selenium solution
(Thermo Fisher Scientific Life Sciences).
Neuronal Differentiation
iPSC colonies were grown to confluence and collected with TrypLE
enzyme (Thermo Fisher Scientific Life Sciences). Neural progenitor
cells (NPCs) were obtained using AggreWell 800 plates (Stem Cell
Technologies) according to the manufacturer’s protocol for NPC
generation in STEMdiff neural induction medium. Briefly, 3 million
iPSCswere cultured in neural inductionmediumandY-27632 (Stem
Cell Technologies)perAggreWell for5days.Neuralaggregateswere
harvested in a 37-mm strainer and plated onto dishes coated with
poly-L-ornithine (PLO) and laminin (ThermoFisher Scientific Life Sci-
ences) in neural inductionmedium for 7 days. Neural rosetteswere
isolated via Rosette SelectionReagent (StemCell Technologies) and
replated onto Matrigel (Thermo Fisher Scientific Life Sciences) or
PLO/laminin-coated plates as NPCs. NPCs were maintained in
DMEM F12 supplemented with 0.5% N-2 supplement, 0.5% B-27
supplement (Thermo Fisher Scientific Life Sciences), 13 sodiumpy-
ruvate (Thermo Fisher Scientific Life Sciences), 13 nonessential
amino acids (Thermo Fisher Scientific Life Sciences), epidermal
growth factor (EGF) (10 ng/ml; Stem Cell Technologies), and FGF2
(10 ng/ml). Differentiation into cortical neurons was per-
formed when NPCs reached ∼40% confluence, replacing EGF
and FGF with brain-derived neurotrophic factor (10 ng/ml;
Stem Cell Technologies).
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Immunocytochemistry
Cells were fixed in cold 4% paraformaldehyde (PFA) (Electron
Microscopy Services) for 15 minutes, rinsed three times for
5 minutes in phosphate-buffered saline (PBS), and stored at
4°C until staining. Cells were permeabilized using 0.25%
Triton-X in PBS for 15 minutes at room temperature, washed
three times for 5 minutes in PBST (0.1% Tween-20 in PBS),
blocked for 1 hour at room temperature using 10% goat serum
and 1% BSA in PBST, and incubated in primary antibodies at 4°C
overnight. Cells were then washed three times for 5 minutes in
PBST and incubated in Alexa Fluor-conjugated secondary anti-
bodies for 1 hour at room temperature in the dark. Cells were
washed in PBST and incubated in 49,6-diamidino-2-phenylindole
(DAPI) (1:1,000) for 10 minutes before being washed in PBST
and stored at 4°C in the dark until imaging. Antibody information
can be found in supplemental online Table 3.
Cell nucleus counts were performed manually by the investi-
gators. In each experiment, multiple images were taken in a non-
biased fashion across multiple independent wells under 310
magnification and sectioned into frames of 675 3 1,000 pixels
for counting.
RNA Fluorescent In Situ Hybridization
Fluorescent in situ hybridization (FISH) was performed as de-
scribed [23]. Briefly, cells grown on coverslips were fixed in cold
4% PFA for 15 minutes and rinsed three times for 5 minutes in
RNase-free PBS (pH 7.4; Thermo Fisher Scientific Life Sciences).
Cellswerepermeabilizedusing0.25%Triton-X (ThermoFisher Sci-
entific Life Sciences) in13RNase-FreePBS for 20minutes at room
temperature. Cells were then washed in RNase-Free PBS. Hybrid-
ization buffer consisting of 50% formamide (Thermo Fisher Scien-
tific Life Sciences), 23 SSC buffer (300 mM NaCl and 30 mM
sodium citrate in nuclease-free water, pH 7.0), 10% dextran sul-
fate (Sigma-Aldrich), and sodium phosphate (50mM, pH 7.0) was
added to cells for 30minutes at 66°C. Thehybridizationbufferwas
removed and replaced with hybridization buffer containing a
(/5TYE563/CCCCGGCCCCGGCCC) probe (batch #609686, Exiqon,
Woburn, MA, http://www.exiqon.com) at 50 nM for 3 hours at
66°C in a dark, humidified chamber. Cells were rinsed with 23
SSC/0.1% Tween (Thermo Fisher Scientific Life Sciences) at room
temperature followed by two rinses for 5 minutes in 0.2% SSC at
66°C. Coverslips were mounted using DAPI with Vectashield re-
agent (Vector Laboratories, Burlingame, CA, http://vectorlabs.
com) and stored in the dark at 4°C until imaging. For coimmuno-
cytochemistry experiments, RNAFISHwasperformedasabove. In
darkness, primaryantibodieswere added in13RNase-freePBSat
concentrations listed above for 2 hours at room temperature.
Cells werewashed in 13 PBS, and secondary antibodywas added
for 1hour at room temperature. Cellswerewashed in 13PBS and
mounted as mentioned previously.
Quantitative Real-Time Polymerase Chain Reaction
RNA was isolated from frozen cell pellets using the RNeasy Plus
Mini Kit (Qiagen, Valencia, CA, http://www.qiagen.com) accord-
ing to the manufacturer’s protocol. Complementary DNA (cDNA)
synthesis was performed using the SuperScript III First-Strand
Synthesis kit (Thermo Fisher Scientific Life Sciences). Relative
gene expression levels were determined in triplicate reactions of
25ngcDNAper reactionusing theSensiFASTSyBRkit (Bioline, Luck-
enwalde, Germany, http://www.bioline.com) on a LightCycler 480
(Roche, Basel, Switzerland, http://www.roche.com). Quantifica-
tion was performed using the –DDCt method. GAPDH was used
as a housekeeping gene with all iPSC-derived cells compared with
their undifferentiated parent line. Total RNA from human skeletal
musclewasobtained froma20-year-oldmale (Clontech,Mountain
View, CA, http://www.clontech.com) and used as a control. Primer
sets are listed in supplemental online Table 3.
Repeat Primed Polymerase Chain Reaction
C9orf72 repeat expansion mutations were determined using the
repeat-primed polymerase chain reaction (PCR) as described by
DeJesus-Hernandez et al. [24]. PCR products were run on an
ABI3730 DNA Analyzer and analyzed using Peak Scanner soft-
ware. The characteristic sawtooth pattern is indicative of the
presence of a repeat expansion.
Fluorescence-Activated Cell Sorting
Cells were collected on day 5 of differentiation using TrypLE en-
zyme, counted, and incubated in fluorescence-activated cell sort-
ing (FACS)buffer (filtered salt-freePBS, 1mMEDTA,25nMHEPES,
pH 7.0, and 1% FBS) with CD309 (20 mL/5 million cells, phycoer-
ythrin conjugated; BD, Franklin Lakes, NJ, http://www.bd.com)
and CD140a (25 mL/5 million cells, Alexa Fluor 647 conjugated;
BD) antibodies for 30minutes on ice in the dark. Sorting was per-
formedat theUCLABroad StemCell ResearchCenter FlowCytom-
etry Core on a FACSAria II cell sorter (BD).
Image and Video Acquisition
Images were taken on an Olympus iX53microscope with a Retiga
EXi Fast 1394camera (QImaging, Surrey, BC, Canada,http://www.
qimaging.com) using Q-Capture Pro 7 software. Videos were
taken as 75-frame sequences with maximum frame speed en-
abled and converted in ImageJ at 7 frames per second, totaling
10 seconds. Confocal microscopy for RNA FISH was performed
at the California NanoSystems Institute Advanced Light Micros-
copy Core on a Leica SP2-1P-FCS microscope. Z-stacks were aver-
aged by frame and merged together using native Leica
Microsystems Confocal software. Confocal images were taken
on a Zeiss LSM 310. Z-stacks were merged together using ImageJ
software.
Individual myotube contractions per second were quantified
manually by ablindedobserver.Only distinct individualmyotubes
were included for quantification, as movements of densely
packed fibers could not reliably be quantified. Only contracting
myotubes were counted.
Statistical Analysis
Statistics were performed in RStudio (version 0.98.978). Data
were resampled 10,000 times using bootstrapping methodology
[25]. Bootstrapping was performed on differences in the median
between test samples. One-way, rank-based analysis of variance
was performed for comparisons of three or more groups.
RESULTS
iPSC Derivation
We obtained skin fibroblasts from four healthy control individu-
als, one patient diagnosed with sporadic FTD, and three FTD pa-
tients harboring aGGGGCC repeat expansion in theC9orf72 gene.
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Figure 1. Small molecule-directed differentiation. (A): Timeline schematic of medium formulations over 36-day protocol. (B): Representative
phase contrast images of myogenic differentiation state over time. Scale bar = 100 mm, 250 mm (far right). (C): Representative immunostaining
shows PAX3 expression beginning at the center of colonies and spreading radially outward at day 5. Scale bar = 250 mm. (D): Gene expression via
qPCR at day 5 reveals high expression of early myogenic markers PAX3 and BRACHYURY T. (E): Gene expression shows preferential induction of
paraxial mesodermmarker TBX6 compared with lateral plate marker FLK1 at day 5 (p = .138). Data shown are single differentiation trials of eight
individual iPSC lines. Lines were derived from clones of a single rGGGGCC carrier diagnosed with FTD (C9-1, C9-2), four control individuals (Con-1,
Con-2, Con-3, Con-4), and clones of a single patient diagnosedwith sporadic FTD (S-1, S-2). Red line represents relative gene expression equal to 1,
representative of undifferentiated iPSCs. (F): FACS sorting on day 5 reveals a cell population that is 48%PDGFRa+/FLK12, representing prospective
paraxial mesoderm progenitors. Line shown is Con-2. Abbreviations: CDM, chemically defined medium; DAPI, 49,6-diamidino-2-phenylindole;
DMSO,dimethylsulfoxide;DN,double-negative;FACS, fluorescence-activatedcell sorting; FTD, frontotemporaldementia; iPSC, inducedpluripotent
stem cell; PE, phycoerythrin; qPCR, quantitative polymerase chain reaction.
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Multiple iPSC lines fromeachpatientwere generatedvia lentiviral
reprogramming vectors containing the canonical factors OCT4,
SOX2, KLF4, and c-MYC and characterized via karyotyping, immu-
nocytochemical staining, and Pluritest analysis (supplemental
online Fig. 1 [22]). Fibroblasts derived from patients with a
C9orf72 repeat expansion were confirmed to contain expanded
GGGGCC repeats via repeat primed PCR and characteristic RNA
foci (supplemental online Fig. 2).
Combinatorial Inhibition of PI3K andGSK3bWith BMP4
and FGF2 Drives iPSCs to a Mesodermal Fate
During embryonic development, somitogenesis and eventual
separation of paraxial, intermediate, and lateral plate mesoderm
is controlled in part bymorphogen gradients of BMPs,Wnts, FGF,
and retinoic acid [26]. BMP4, in tandemwith high concentrations
of FGF andWnt signaling, promotes development of the paraxial
mesoderm along the primitive streak into the dermomyotome,
which eventually forms the skeletal musculature of the body
[26–28]. Studies have shown that inhibition of PI3K enhances
the differentiation of human embryonic stem cells into mesoder-
mal lineages through the promotion of activin A and nodal signal-
ing [29]. Likewise, DMSO has been previously shown to improve
differentiation efficiencies of pluripotent stem cells into terminal
cell lineages through activation of the retinoblastoma protein
[30]. Thus, we combined these two differentiation enhancement
strategies with developmental morphogens to drive iPSCs into a
mesodermal lineage (Fig. 1A).
Differentiation of sparsely plated iPSC colonies on vitronectin-
coated plates or coverslips was initiated 1–3 days after passaging,
when colonies were of small to medium size (approximately
250–400mm).Weexposed iPSCs to1.5%DMSO inTeSR-E8medium
for24hours toprimecells fordifferentiation [30].AfterDMSOtreat-
ment, cells were exposed to a chemically defined medium supple-
mentedwith FGF2, the PI3K inhibitor LY294002, and BMP4, termed
CDM FLyB, as previously described [31]. Inhibition of GSK3b pro-
motesWnt/b-catenin signaling,which in turnpromotes cellular dif-
ferentiation to amesodermorendoderm fate [14, 15, 32]. Basedon
these studies, we added the GSK3b inhibitor, CHIR99021, to CDM
FLyB during the initial 36 hours of differentiation (FLyBC) followed
by withdrawal of BMP4 and CHIR99021 for 5.5 days.
At day 5, we observed PAX3+ mesodermal progenitors present
at the center of differentiating iPSC colonies,makingup,5%of the
total cell population; however, we did not detect any PAX7+ cells at
that time point (Fig. 1C). Analysis by quantitative PCR (qPCR)
showed a significant induction of mesodermal genes BRACHYURY
T and PAX3, with a concomitant loss of pluripotency markers
NANOG and OCT4 (Fig. 1D, supplemental online Fig. 3A, 3B). Addi-
tionally, we observed increased expression of TBX6 compared with
FLK1, indicating a favored differentiation intoparaxial versus lateral
plate mesoderm (Fig. 1E). We did not detect any significant differ-
ence in gene expression at day 5 based on carrier status between
8 total lines tested (supplemental online Fig. 3C).
To gauge the efficiency of paraxial mesoderm production,
we used FACS to sort prospective paraxial mesoderm progeni-
tors based on a PDGFRa+/FLK12 population [5, 16]. We first ob-
served that 1.5% DMSO-treated cells contained 92% more
PDGFRa+/FLK12 cells than those left untreated (supplemental
online Fig. 4). We observed an overall cell population of up to
48%PDGFRa+/Flk12, a proportion substantially higher thanpre-
viously published protocols using embryoid bodies (Fig. 1F) [33].
Attempted recovery and propagation of the sorted population
failed in every trial after replating cells in CDM FLy onto vitronectin-,
Matrigel-, or gelatin-coated plates at various densities, even in
the presence of the Rho kinase (ROCK) inhibitor Y-27632.
MB-1 Medium Followed by DMEM and Low Serum
Promotes Skeletal Myotube Formation
Based on our day-5 analysis, we sought to find medium formula-
tions and time frames that allowed paraxial mesoderm progeni-
tors to continue to propagate in vitro while retaining their cell
identity after 7 days. We first prepared myogenic induction me-
dium, as in Darabi et al. [7]; however, the mesoderm progenitors
failed to propagate in this formulation (data not shown).We then
tested a serum-containing medium, MB-1, which allows for con-
tinued propagation of myoblasts and initiation of the myogenic
program via TBX1 and TBX4 activation upstream of MYF5 and
MYOD1 [10]. After 7 days in vitro and beyond, iPSC-derived me-
sodermal progenitors continued to propagate in MB-1 medium,
and cellularmorphology began to showelongation andalignment
of progenitor myocytes, suggestive of maturation (Fig. 1B).
Before the addition of CHIR99021 to our protocol, we sought to
test multiple timelines of selected medium formulations that best
yieldmyogenic inductionbasedongeneexpressionofPAX3,MYOG,
MYH2 (myosin heavy chain 2, referred to hereafter as MHC), and
MYOD1 after 36 days in vitro (supplemental online Table 2). The
best-performing protocol, group E, showed high induction of
PAX3, MYOG, and MYOD1, indicative of a cell population of myo-
cytes in the mid-stages of differentiation together with a pool of
PAX3+ progenitors and was selected for further study (supplemental
online Fig. 5) [26]. The expression ofMHC in group E cells was lower
than in skeletal muscle RNA obtained from an adult, indicating
that iPSC-derived myocytes are likely immature at day 36. This
was supported by qPCR of acetylcholine receptor subunits, which
showed high expression of the fetal g subunit compared with the
adult « subunit, and immunostaining of MHC, which displayed
both embryonic and adult isoforms (supplemental online Fig. 6).
During development,myogenesis is governed by the progres-
sive expression of transcription factor genes such as PAX3, PAX7,
MYF5, MYOD1, and MYOG, representing distinct genetic land-
marks of maturing myotubes [26]. During the switch from the
PAX7+ myoblast stage to terminal differentiation, PAX7 expres-
sion is suppressed andMYOG is upregulated, marking distinct cell
populations [34, 35]. We observed this phenomenon in vitro, as
PAX7 and MYOG marked mutually exclusive cell populations, in-
dicatingamixedpopulationof cells at differentdifferentiation stages
(Fig.2A). Interestingly,weobservedareasofnearly100%PAX7+cells,
whereasotherregionsdisplayedamixtureofcellsatvariousstagesof
nuclear fusion (as defined by $ 3 concurrent nuclei), perhaps indic-
ative of uniquemicrosignaling environments (Fig. 2B, 2C). In all cases
observed,multinucleated cellswereMYOG+/PAX72 (Fig. 2D). Across
four cell lines at day 36, we observed up to 64% of nuclei expressing
MYOG(median=44.8%), indicatinghighlyefficientdifferentiationto-
ward a skeletal muscle fate (Fig. 2E). We also observed a mix of
intermediate- and late-stage skeletal muscle as shown by desmin
(DES) andMHC staining, respectively (Fig. 2F). Gene expression via
qPCR showed high upregulation of late-stage skeletal muscle tran-
scriptionfactorsMYOGandMYOD1, aswell asupregulationofMHC
and the cholinergic receptor CHRNA1 compared with undifferenti-
ated iPSCs (Fig. 3). Using RNA obtained from a 20-year-old adult’s
skeletalmuscleasacomparison forgeneexpression,weobserveda
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significant increase in iPSC-derived muscle expression of CHRNA1
and PAX3 and decreased expression ofMHC, supporting an imma-
ture phenotype of iPSC-derived muscle. PAX3 continued to be
expressed, although at lower levels than on day 5, suggestive of the
existenceofaprogenitoror satellite-cell poolwithin thepopulation.
Serum-FreeMediumPromotes Terminal Differentiation
and Spontaneous Activity of Skeletal Myotubes
To our knowledge, four groups have reported spontaneous
twitching of skeletalmyotubes after differentiation fromaplurip-
otent state without the use of transgene overexpression [4, 14,
17, 18].We did not observe any spontaneous twitching in our cell
cultures after 36 days in vitro and hypothesized thatmore time in
culture was required to reach maturity (Fig. 4A). After 63 total
days in fusion medium, we observed brief, spontaneous contrac-
tions in a small set ofmyotubes in addition tomyotube thickening
(Fig. 4B). Upon observation, we switched the medium of cells
grown in tandem to a serum-free, N-2-based formulation, which
promotes terminal differentiation [4, 14]. Seven to 10 days after
the addition of N-2 medium, we observed robust spontaneous
contractions throughout the cell cultures (supplemental online
Movies 1 and 2). These cells continually contractedwithout exog-
enous stimulation formore than3weeksuntil fixationonday120.
Following the protocols in Figures 1A and 4A, we quantified
the ratio of PAX7+ or MYOG+ cells on day 36 compared with
day 120 in a single-carrier iPSC line (Fig. 4C, 4D). At day 36, we ob-
servedup to90%conversion intoPAX7+orMYOG+myogenic cells.
We also observed a 19.6% decrease in the amount of PAX7+ cells
over time, suggesting that cells may continually become commit-
ted to terminal differentiation over time in vitro. Alternatively,
differentiationefficiencymayvary across trials, resulting inhigher
percentages of TUBB3+ neural crest-derived cells (supplemental
online Fig. 7), which rely on similar signaling pathways during de-
velopment [36, 37]. Nevertheless, a large amount of MHC+ myo-
tubes surrounded by PAX7+ progenitor cells remained in culture
even after 4 months, perhaps indicative of the satellite cell niche
that is observed in vivo (Fig. 4E).
Because of the robust terminal differentiation phenotype ob-
servedafter the addition ofN-2medium,weaimed tooptimize the
time frame of our protocol via the addition of N-2 medium after
10 days of fusionmedium, or 22 days total from the start of differ-
entiation (Fig. 4F). Using this strategy, we observed robust sponta-
neous myotube contractions as early as 34 days, which is the
quickest time reported, to our knowledge. The median rate of
spontaneous contractions increased over a 12-day period from
0.1 contractions/second to 0.3 (Fig. 4G, supplemental online
Movie 3). Additionally, myotubes displayed striations as visual-
ized by the sarcomeric protein TITIN (Fig. 4H). Importantly, cells
were able to be passaged on day 23 or freeze-thawed on day 30
onto Matrigel-coated plates into N-2 medium with or without
ROCK inhibitor, allowing for experimental scaling and long-
term storage.
Skeletal Myotubes Derived From C9orf72 Repeat
Expansion Carriers Contain RNA Foci but Do Not Exhibit
TDP-43 Mislocalization
One of the three main hypotheses of how C9orf72 repeat expan-
sions lead to ALS/FTD is the accumulation of RNA foci that may se-
quester important RNA-binding proteins, leading to splicing and
Figure 2. iPSCs form multinucleated, MYOG+ myotubes by day 36. (A):
Immunostaining of myogenic cells at day 36 reveals mutually exclusive
PAX7+ and MYOG+ cell populations representing unique satellite cell pro-
genitor and terminally committed populations. Scale bar = 100 mm. (B):
Immunostaining for PAX7 on day 36 reveals certain regions with near-
100%PAX7+cells,possiblybecauseofuniquemicrosignalingenvironments.
Scale bar = 250mm. (C): Immunostaining forMYOG on day 36 shows cer-
tain regionswithmanymyotubesactivelyundergoingnuclear fusion. Scale
bar=100mm. (D):Multinucleatedmyotubesundergoingnuclear fusionon
day 36 are alwaysMYOG+. Scale bar = 50mm. (E):Quantification of myo-
genic induction byMYOG+ cells across four individual iPSC lines. Each data
pointrepresents.125cellnucleicounted inseparatewells.Scalebar=100
mm. (F): Immunostainingatday36shows largeareasof cytoskeletalMHC+
and DES+myogenic cells, representing terminally differentiated and inter-
mediate cell populations, respectively. Scale bar = 250mm (left), 100mm
(right). Abbreviations: DAPI, 49,6-diamidino-2-phenylindole; iPSC, induced
pluripotent stem cell; MHC, myosin heavy chain.
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transcriptome alterations [19, 38]. To determine the transcription
levels of C9orf72 in skeletal muscle, we performed variant-specific
qPCR on both iPSC-derived skeletal muscle at day 36 and iPSC-
derived neurons. The results show that all variants of C9orf72
are expressed in both adult and iPSC-derived skeletal muscle,
with iPSC-derived neurons showing the highest expression lev-
els (supplemental online Fig. 8), as reported by other groups
(Fig. 5A) [39]. We then performed RNA FISH on iPSC-derived
skeletal muscle, which revealed the presence of RNA foci in
MHC+myofibers, indicating that RNA-related pathology in brain
may also be present in muscle (Fig. 5B).
In IBMPFD, patients can exhibit identical TDP-43 and ubiqui-
tin pathology in both brain and skeletal muscle [21]. Given the path-
ological overlap of IBMPFD with C9orf72-related motor neuron
Figure 3. iPSC-derived skeletal muscle cells express key myogenic genes at day 36. Myogenic genes PAX3,MYOG,MYOD1, CHRNA1, andMHC
all revealed high expression levels comparedwith undifferentiated iPSCs.CHRNA1 (p = .0391) andPAX3 (p = .0381)were upregulated compared
with HSM, whereasMHC was downregulated (p = .0017). Data shown are single differentiation trials of eight individual iPSC lines. Lines were
derived from clones of a single repeat expansion carrier diagnosed with FTD (C9-1, C9-2), four control individuals (Con-1, Con-2, Con-3, Con-4),
and clones of a single patient diagnosed with sporadic FTD (S-1, S-2). Red line represents relative gene expression equal to 1, representative
of undifferentiated iPSCs. HSMrepresents adult human skeletalmuscle,with each data point comparedwith each parent iPSC line, respectively.
p, p, .05; pp, p, .01. Abbreviations: FTD, frontotemporal dementia; HSM, human skeletal muscle; iPSC, induced pluripotent stem cell.
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Figure 4. The number of PAX7+ progenitor cells decreases over time in vitro. (A): Timeline schematic of medium formulations over a 120-day
protocol. A small percentage of cells in fusion medium reach a spontaneously contractile state within 75 days. Switching to a serum-free N-2
mediumpromotes terminal differentiation coincidentwith spontaneous contractility within 7–10 days. Cells were grown on vitronectin-coated
coverslips to prevent detachment of skeletalmyotubes. (B): Phase contrast image of skeletalmyotubes at day 70 showmyotube thickening over
time. Scale bar = 250mm. (C): Immunostaining ofmyotubes for PAX7 andMYOGat days 36 and120. Blue nuclei are stainedwithDAPI. Scale bar =
100 mm (left), 250 mm (right). (D): Quantification of myogenic cells on day 36 compared with day 120 shows a decrease in the percentage of
PAX7+ cells over time (p = .0066)with coincident increases inMYOG+ cells (p = .023) and unidentified DAPI+ nuclei (p = .0446). p, p, .05; pp, p,
.01; n. 75 cells counted per data point). “Other” refers to unknown cell nuclei stained with DAPI. Bar plots represent the median. Data rep-
resents a single iPSC line (C9-2) differentiated in tandem plates in a single batch. (E): Immunostaining ofmyotubes at day 120 reveal PAX7+ cells
intermingledwith thickenedMHC+myotubes, reminiscent of a satellite cell niche. Scale bar = 100mm. Line is C9-2. (F): Timeline schematic of the
optimized protocol for obtaining spontaneously contractile myotubes in less than 36 days. (G): Quantification of single myotube contractions
per second increased over a 12-day period. Myotube contractions per second were significantly higher on day 40 compared with day 34
(p = .0026) which continued in trend by day 46 (p = .0872). Red dots represent median values. iPSC line is C9-2. pp, p , .01; ppp, p , .001.
(H): Representative immunostaining of myotubes at day 36 reveal structural striations based on the presence of the sarcomeric protein TITIN.
Scale bar = 50mm. Abbreviations: CDM, chemically definedmedium; DAPI, 49,6-diamidino-2-phenylindole; iPSC, induced pluripotent stem cell;
MHC, myosin heavy chain.
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Figure 5. Skeletal muscle derived from repeat expansion carriers contain RNA foci but do not exhibit mislocalized TDP-43. (A): qPCR detection
of three separate transcript variants of C9orf72 in adult HSM, iPSC-derived muscle at day 36, and iPSC-derived cortical neurons (variant 1:
NM_145005.6, variant 2: NM_018325.4, variant 3: NM_001256054.2). Data shown are pooled wells from single differentiation trials of four
individual iPSC lines. Skeletal muscle lines were derived from clones of a single repeat expansion carrier diagnosed with FTD/ALS (C9-1,
C9-2), one control individual (Con-4), and a single patient diagnosedwith sporadic FTD (S-2). Neurons were derived from clones from two patients
(Figure legend continues on next page.)
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disease, we probed iPSC-derived skeletal myotubes at day 120 for
TDP-43 mislocalization (Fig. 5C). We did not detect any instances
of cytoplasmic TDP-43, indicating thatC9orf72-relatedmotorneuron
disease does not display TDP-43 pathology or that these cells are too
immature to properly model muscle pathology. Tu¨rk et al. have pre-
viously reported on a C9orf72 case study that displayed p62- and
ubiquitin-positive inclusions in patient muscle biopsy [40]. We also
probed iPSC-derived skeletal muscle for ubiquitin and p62 but did
not observe any positive inclusions in our cells (data not shown).
More recent studieshave shown that C9orf72-associated iPSC-
derivedneurons containmislocalizedRanGAP1nuclear punctaand
damagednuclearenvelope inDrosophilaoverexpressingexpanded
GGGGCC repeats, indicating impairednucleocytoplasmic transport
[41, 42]. Skeletal myotubes derived from expansion carriers and
controls both exhibited typical RanGAP1 perinuclear staining with
weaker distributions in the cytoplasm and nucleoplasm, with rare
nuclear aggregates in both cases and controls (Fig. 5D) [41].We in-
frequently observed aberrant nuclear membrane folding, as high-
lighted by LMNA staining and mirrored by RanGAP1 in skeletal
muscle, but this phenomenonwaspresent inbothcarriersandcon-
trols (Fig. 5E). Taken together, these results suggest that observed
C9orf72-associatedphenotypesmaybe restricted toneuronal sub-
types, perhaps because of its high expression [39].
DISCUSSION
Our study adds novel methodology to the growing body of proto-
cols deriving skeletal myotubes from pluripotent stem cells for
use in disease modeling, developmental studies, or drug discov-
ery. There have been several studies thus far attempting a
transgene-free approach, with various efficiencies [14, 15, 17,
18, 32, 43]. We likewise find that promotion of Wnt signaling
via GSK3b inhibition strongly influencesmesoderm commitment,
and the combination of BMP4 and FGF2 signaling results in highly
efficient mesoderm induction while recapitulating normal devel-
opment as evidenced through a time-specific activation of early
myogenic genes BRACHYURY T and PAX3, followed by PAX7
and late-stage markers such as MYOG, MYOD1, andMHC. Inter-
estingly, we were still able to obtain myogenic cells with addition
of BMP4 and FGF2 before adding CHIR99021 to our protocol, sug-
gesting an important and nonindispensible role of BMP4 in myo-
genic induction, contrary to previous reports [18].
Our study differs from previously published studies that re-
ported lowmyogenic induction efficiencies in the presence of se-
rum [33, 43, 44]. In our protocol, we use MB-1 medium, which
contains 15% FBS, followed by a fusion medium consisting of
2% horse serum, to achieve myogenic induction of up to 90% in
36days. However,we likewise find that a serum-freeN-2medium
necessitates myoblast fusion [4, 5, 7, 11, 14] enabling spontane-
ously contractilemyotubes within 34 days.We believe this differ-
ence may be caused by the key additions of DMSO at the start of
our protocol, which primes cells for differentiation, and PI3K
inhibition,which has been shown to drive cells into amesodermal
lineage via activin A and nodal signaling [29–31]. Future optimi-
zation using serum-free medium formulations or cell sorting for
markers such as NCAM or AchR [4, 15] may allow for use of
iPSC-derived muscle in therapeutic regenerative medicine.
Success in maintaining a self-renewing satellite cell popula-
tion in vitro would serve as an invaluable tool for future regener-
ative medicine purposes [45]. We observed that PAX7+ cells
frequently lie adjacent to MHC+ myofibers, reminiscent of their
in vivo niche between the myofiber plasma membrane and basal
lamina (Fig. 4D). In tandem trials, we also observed a decreasing
number of PAX7+ cells in vitro over time, indicating commitment
to terminal differentiation (Fig. 4B). However, it is also possible
that the 5% increase in MYOG+ cells and 19.6% decrease in
PAX7+ cells are caused by initial overall decreased production
of PAX7+ cells or increased production of neural crest-derived cell
types. Further studies using a PAX7 reporter are needed to assess
the percentage of PAX7+ cells that commit to terminal differenti-
ation over time, what percentage of these cells coexpress the
myogenic commitment factorMYF5, or whether addition ofmor-
phogens such as Wnt7a can maintain a symmetrically renewing
population of progenitors indefinitely [46, 47].
The extracellular matrix (ECM) provides elasticity and stiff-
ness qualities that exert strong influence over skeletal muscle
proliferation and regenerative capacity [48–51]. The importance
of the substrate in our studies is demonstrated by a failed recov-
ery of day-5 mesodermal progenitors after FACS onto Matrigel,
whereas the same Matrigel substrate can be used for passaging
and expansion of cells later in differentiation on day 23. We be-
lieve this may be caused by Matrigel’s stiffness (Young’s modulus =
0.45 kPa [52]) beingmore similar to reported human adultmuscle
stiffness (0.5 kPa), allowing PAX7+ progenitors, which were not
present at day 5, to proliferate onMatrigel [53]. Likewise, we oc-
casionally observed detachment of skeletal myotubes along the
edges of wells during terminal differentiation or because of
strong contractile force (supplemental online Movie 1). Indeed,
contractile cells remained attached for longer periods of time
in dense areas or via growth on coverslips, the edges of which
seemed to provide anchoring points and tension for contractile
myotubes to attach, similarly to other methods using microfiber
arrays or stainless-steel meshes [54, 55]. Using this strategy, we
were able to observe contractilemyotubes for.2weeks. Further
improvements may be made by more accurately mimicking in
vivo properties and signaling cues of the ECM.
To demonstrate variability between iPSC lines and reproducibil-
ity of our protocol, we performed single differentiation trials among
eight independent cell lines derived from six total individuals. As
noted by others, we believe that the variability observed in gene ex-
pression between iPSC lines in our experimentsmay be largely influ-
enced by imperfect initial seeding density [14, 15] but could also be
influencedby interline variability basedongenetic backgroundof in-
dividual donors [56–58] which may be predictive of future
(Figure legend continued from previous page.)
diagnosed with behavioral variant FTD (C9-3, C9-4). Red line represents relative gene expression equal to 1, representative of undifferentiated
iPSCs. ppp, p, .001. (B): Confocal image shows an MHC+ iPSC-derived skeletal muscle cell containing two nuclear RNA foci. White dotted line
indicates location of cell nucleus, yellow arrows indicate foci. Scale bar = 15 mm. (C): Immunostaining of TDP-43 reveals no instance of mis-
localization in iPSC-derived skeletal muscle at day 120 in carrier or control lines. Scale bar = 50 mm. (D): RanGAP1 immunostaining shows
typical perinuclear and nuclear localization in skeletal myotubes. Scale bar = 50 mm. (E): Nuclear folding evidenced by LMNA and RanGAP1
immunostaining is infrequently present in skeletal muscle derived from carriers and controls. Scale bar = 50mm. Abbreviations: ALS, amyotrophic
lateral sclerosis; DAPI, 49,6-diamidino-2-phenylindole; FTD, frontotemporal dementia; HSM, human skeletal muscle; iPSC, induced pluripotent
stem cell; LMNA, lamin A/C; MHC, myosin heavy chain; qPCR, quantitative polymerase chain reaction.
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differentiation potential [59]. For instance, lines Con-3 and Con-4
each had low levels ofmyogenic gene expression (Fig. 3), suggesting
that they may be intrinsically skewed against mesodermal differen-
tiation. Additional differentiation trials and iPSC lines are needed to
accurately concludewhich of these factors plays the governing role.
Evidence in animal models of ALS suggest that collapse of the
neuromuscular junction and axonal retraction precede the death
of themotor neuron, yet the role of skeletalmuscle in the process
remains largely unknown [60, 61]. We first determined that all
variants of C9orf72 are expressed in iPSC-derived skeletalmuscle,
but at lower levels than iPSC-derivedneurons. Interestingly, in the
two lines we studied, repeat expansion carriers displayed a trend
of higher levels of variants 1 and 2, contrary to most reports of
mRNA haploinsufficiency in patient-derived tissues and cell lines
(Fig. 5A) [24, 62], which warrants further investigation. We addi-
tionally probed for known pathological features associated with
C9orf72-related ALS/FTD but found no evidence of TDP-43 mis-
localization or ubiquitin/p62-positive inclusions, perhaps be-
cause of low levels of C9orf72 expression. In the vast majority
of cases, RanGAP1wasproperly localized to theperinuclearmem-
brane (Fig. 5D), with few cases of aggregated RanGAP1within the
nucleus, seen in carriers and controls. In some instances, we ob-
served a nuclear membrane phenotype via LMNA and RanGAP1
staining similar to that seen in patients with Hutchinson-Gilford
progeria [63]. This phenotype, however, was observed in both
carrier and control-derived cells (Fig. 5E), consistent with report-
ed basal rates of altered nuclei of ∼10% [64]. Nevertheless, the
localization of C9orf72 isoform b in the nuclear membrane and
altered nuclear membrane proteins in patient postmortem tis-
suesmake a compelling case for the involvement of nuclearmem-
brane breakdown in C9orf72-related disease [39, 65].
CONCLUSION
The data provided offer a robust method to obtain skeletal myotubes
from pluripotent stem cells. This protocol can be adapted for
obtaining skeletal myotubes from iPSCs from a variety of diseases
for use in drug discovery and modeling of neuromuscular and mus-
culoskeletal diseases. Further studies such as the tandem derivation
of iPSC-derivedmotorneuronsandskeletalmuscle areneeded tode-
terminethecontribution, ifany,oftheskeletalmuscleandneuromus-
cular junction in C9orf72-related ALS and other motor neuron
diseases.
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